{"id":"tetravalent-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":{"setId":"280ee057-3488-4d77-b510-8bc733eeca1e","title":"DENGVAXIA (DENGUE TETRAVALENT VACCINE, LIVE) KIT [SANOFI VACCINES US INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tetravalent vaccines contain antigens from four different disease agents or variants, triggering both humoral (antibody) and cell-mediated immune responses. This approach provides broader protection by targeting multiple circulating strains or related pathogens simultaneously, reducing the likelihood of infection across the covered serotypes or variants.","oneSentence":"A tetravalent vaccine stimulates the immune system to produce antibodies and cellular immunity against four distinct pathogenic targets or strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:34.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Protection against four dengue serotypes (dengue tetravalent vaccine)"}]},"trialDetails":[{"nctId":"NCT05921448","phase":"EARLY_PHASE1","title":"Vaccine Pandemic Preparedness Through Airway Immunology Characterization","status":"ACTIVE_NOT_RECRUITING","sponsor":"Copenhagen Respiratory Research","startDate":"2025-05-19","conditions":"Influenza, Human","enrollment":60},{"nctId":"NCT07256912","phase":"PHASE4","title":"A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia","status":"NOT_YET_RECRUITING","sponsor":"International Agency for Research on Cancer","startDate":"2026-04-01","conditions":"Vaccine Effectiveness, HPV Vaccination, Single Dose","enrollment":1266},{"nctId":"NCT02410733","phase":"PHASE1","title":"Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2015-03","conditions":"Melanoma","enrollment":119},{"nctId":"NCT07183371","phase":"PHASE2","title":"A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2025-12-15","conditions":"Malaria,Falciparum","enrollment":360},{"nctId":"NCT06805487","phase":"PHASE1","title":"Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-24","conditions":"Zika Virus","enrollment":27},{"nctId":"NCT06754384","phase":"PHASE1, PHASE2","title":"Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-01-15","conditions":"Hand, Foot, and Mouth Disease (HFMD), Herpangina","enrollment":552},{"nctId":"NCT07087912","phase":"PHASE4","title":"Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-10","conditions":"Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Systemic Lupus Erythematosus (SLE)","enrollment":477},{"nctId":"NCT07047521","phase":"PHASE3","title":"A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2025-11-07","conditions":"Dengue Fever","enrollment":496},{"nctId":"NCT06615375","phase":"PHASE2","title":"A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine","status":"RECRUITING","sponsor":"LimmaTech Biologics AG","startDate":"2024-11-12","conditions":"Shigellosis","enrollment":120},{"nctId":"NCT06579755","phase":"PHASE3","title":"A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-20","conditions":"Dengue Fever","enrollment":800},{"nctId":"NCT04486638","phase":"","title":"Dengvaxia US Pregnancy Registry","status":"RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-01-01","conditions":"Dengue Virus Infection","enrollment":500},{"nctId":"NCT04983030","phase":"PHASE1, PHASE2","title":"Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boris Juelg, MD PhD","startDate":"2022-04-01","conditions":"HIV, Acquired Immunodeficiency Syndrome, Immunologic Deficiency Syndrome, Acquired","enrollment":36},{"nctId":"NCT06741683","phase":"PHASE2, PHASE3","title":"A Study of Dengue Tetravalent Vaccine (TDV) in Healthy Participants in Japan","status":"COMPLETED","sponsor":"Takeda","startDate":"2025-01-31","conditions":"Dengue Fever","enrollment":187},{"nctId":"NCT06060067","phase":"PHASE3","title":"A Study of Dengue Vaccine in Healthy Children, Teenagers and Adults in India","status":"COMPLETED","sponsor":"Takeda","startDate":"2024-03-29","conditions":"Healthy Volunteers","enrollment":480},{"nctId":"NCT02747927","phase":"PHASE3","title":"Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-04-26","conditions":"Healthy Volunteers","enrollment":20099},{"nctId":"NCT05710224","phase":"PHASE2","title":"Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-02-15","conditions":"Dengue","enrollment":1364},{"nctId":"NCT05479370","phase":"PHASE3","title":"Immunogenicity Trial of 3 Influenza Vaccines","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2022-09-29","conditions":"Influenza Vaccination","enrollment":366},{"nctId":"NCT06125691","phase":"PHASE1","title":"Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Influenza, Human","enrollment":139},{"nctId":"NCT04551677","phase":"PHASE4","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":90},{"nctId":"NCT04109222","phase":"PHASE4","title":"Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-30","conditions":"Influenza","enrollment":90},{"nctId":"NCT05050318","phase":"PHASE4","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-09-08","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":90},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT03746015","phase":"PHASE2","title":"Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-12-28","conditions":"Dengue Fever","enrollment":30},{"nctId":"NCT07158190","phase":"","title":"Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-06-30","conditions":"Dengue","enrollment":30},{"nctId":"NCT06843226","phase":"","title":"A Study in Children and Adolescents on the Effectiveness of Takeda's Licensed Dengue Vaccine TDV Against Hospitalization Due to Dengue Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-05","conditions":"Dengue Fever","enrollment":70000},{"nctId":"NCT03728881","phase":"PHASE3","title":"Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":1240},{"nctId":"NCT06665035","phase":"PHASE3","title":"A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-06-16","conditions":"Dengue Fever","enrollment":212},{"nctId":"NCT03999996","phase":"PHASE3","title":"Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-11-12","conditions":"Dengue Fever","enrollment":365},{"nctId":"NCT02935686","phase":"PHASE1, PHASE2","title":"A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2017-03-31","conditions":"Healthy","enrollment":155},{"nctId":"NCT02788045","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2016-07-08","conditions":"Healthy","enrollment":201},{"nctId":"NCT05082285","phase":"PHASE2","title":"A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-11-29","conditions":"Infections, Meningococcal","enrollment":724},{"nctId":"NCT05507450","phase":"PHASE2","title":"Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-09-07","conditions":"Dengue Disease, Dengue Virus","enrollment":1271},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT05093829","phase":"PHASE3","title":"Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-03-24","conditions":"Meningitis","enrollment":1325},{"nctId":"NCT03694392","phase":"","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2018-09-16","conditions":"Influenza, Pneumonia, Lower Respiratory Tract Infection","enrollment":2776278},{"nctId":"NCT06906692","phase":"","title":"Meningococcal Vaccination in Patients on Complement Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-03-25","conditions":"Myasthenia Gravis Generalised, Vaccination, Complement System","enrollment":35},{"nctId":"NCT01997450","phase":"","title":"A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age","status":"TERMINATED","sponsor":"MedImmune LLC","startDate":"2013-12-02","conditions":"Influenza Vaccine Effectiveness","enrollment":4121},{"nctId":"NCT03898986","phase":"PHASE1","title":"The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets","status":"COMPLETED","sponsor":"Stanford University","startDate":"2019-10-08","conditions":"Influenza","enrollment":18},{"nctId":"NCT03932682","phase":"PHASE3","title":"Efficacy Study With QIVc in Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-05-13","conditions":"Influenza, Human","enrollment":5723},{"nctId":"NCT04786457","phase":"PHASE1","title":"ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2020-11-30","conditions":"Dengue","enrollment":10},{"nctId":"NCT03307915","phase":"PHASE1","title":"A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-03-05","conditions":"Human Immunodeficiency Virus","enrollment":25},{"nctId":"NCT02678455","phase":"PHASE2","title":"Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-03","conditions":"Dengue","enrollment":192},{"nctId":"NCT03312699","phase":"PHASE1","title":"Effects of Aging on Primary and Secondary Vaccine Responses","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-09-19","conditions":"Influenza, Hepatitis A, Typhoid","enrollment":54},{"nctId":"NCT04782323","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-04-13","conditions":"Influenza","enrollment":839},{"nctId":"NCT05895955","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mahidol University","startDate":"2023-11-04","conditions":"Influenza","enrollment":290},{"nctId":"NCT05401448","phase":"EARLY_PHASE1","title":"Non-specific Effects of FLU-MMR Vaccines in Adults","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2021-06-01","conditions":"COVID-19","enrollment":638},{"nctId":"NCT04056117","phase":"PHASE1, PHASE2","title":"A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2019-09-02","conditions":"Shigellosis","enrollment":596},{"nctId":"NCT02741128","phase":"PHASE2","title":"Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-06","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Human Immunodeficiency Virus","enrollment":133},{"nctId":"NCT05229354","phase":"PHASE2","title":"Dengue Controlled Human Infection Model in Dhaka, Bangladesh","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Kirkpatrick","startDate":"2021-12-11","conditions":"Dengue","enrollment":192},{"nctId":"NCT06142461","phase":"PHASE2","title":"Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System","status":"WITHDRAWN","sponsor":"PharmaJet, Inc.","startDate":"2024-05-31","conditions":"Vaccine Reaction","enrollment":""},{"nctId":"NCT05769569","phase":"PHASE1","title":"Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission","status":"WITHDRAWN","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2023-09-01","conditions":"HIV-1-infection","enrollment":""},{"nctId":"NCT06385821","phase":"PHASE3","title":"A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2022-09-21","conditions":"Influenza, Influenza A, Influenza, Human","enrollment":824},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":"Influenza, Human","enrollment":471},{"nctId":"NCT05501561","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-08-25","conditions":"Influenza, Human","enrollment":1056},{"nctId":"NCT02948829","phase":"PHASE2","title":"Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-03","conditions":"Healthy Volunteers","enrollment":200},{"nctId":"NCT06286488","phase":"PHASE4","title":"Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated Influenza","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical University of Warsaw","startDate":"2020-09-15","conditions":"Influenza, Obesity, Pregnancy; Infection","enrollment":1500},{"nctId":"NCT02406729","phase":"PHASE3","title":"Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine","status":"UNKNOWN","sponsor":"Butantan Institute","startDate":"2016-02-22","conditions":"Dengue","enrollment":16935},{"nctId":"NCT04313244","phase":"PHASE3","title":"Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to <15 Years","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-05-15","conditions":"Dengue Fever","enrollment":614},{"nctId":"NCT04023708","phase":"","title":"Observational Study to Evaluate the Safety of CYD Tetravalent Dengue Vaccine (CYD-TDV) in Pregnant Women and Their Offsprings Inadvertently Exposed During Pregnancy","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-03-11","conditions":"Dengue Virus Infection","enrollment":104},{"nctId":"NCT04035278","phase":"PHASE1","title":"A Phase 1 Safety Study of Dengusiil in Healthy Adults","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-12-17","conditions":"Prevention of Dengue Fever","enrollment":60},{"nctId":"NCT06127693","phase":"","title":"Childhood Adversity, Inflammatory Reactivity and Persistent Pain","status":"COMPLETED","sponsor":"University of Cape Town","startDate":"2022-06-21","conditions":"Chronic Pain, Central Sensitisation, Immune Response","enrollment":101},{"nctId":"NCT05044195","phase":"PHASE3","title":"A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2021-09-30","conditions":"Influenza, Human","enrollment":2044},{"nctId":"NCT06029933","phase":"","title":"Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years","status":"RECRUITING","sponsor":"Kaiser Permanente","startDate":"2023-08-17","conditions":"Influenza, Community-acquired Pneumonia, Cardiovascular Events","enrollment":960000},{"nctId":"NCT05107375","phase":"PHASE3","title":"Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine","status":"COMPLETED","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2021-09-03","conditions":"Coronavirus Disease 2019","enrollment":299},{"nctId":"NCT05869201","phase":"PHASE2, PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-10-06","conditions":"Influenza, Influenza, Human, Influenza Viral Infections","enrollment":450},{"nctId":"NCT03803618","phase":"","title":"Dengue Effectiveness Study in the Philippines","status":"COMPLETED","sponsor":"University of the Philippines","startDate":"2017-09-01","conditions":"Dengue, Severe Dengue, Virologically Confirmed Dengue","enrollment":2081},{"nctId":"NCT03465254","phase":"","title":"Dengue Serostatus Study in the Philippines","status":"UNKNOWN","sponsor":"University of the Philippines","startDate":"2016-11","conditions":"Dengue, Severe Dengue, Dengue Fever","enrollment":2996},{"nctId":"NCT01511250","phase":"PHASE2","title":"Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years","status":"COMPLETED","sponsor":"Takeda","startDate":"2011-11-16","conditions":"Healthy","enrollment":360},{"nctId":"NCT05761002","phase":"NA","title":"Human Papilloma Virus Genotypes and Treatment Outcomes of Intralesional Immunotherapy of Anogenital Warts","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2022-06-01","conditions":"Human Papilloma Virus, Anogenital Wart","enrollment":58},{"nctId":"NCT04133987","phase":"PHASE2","title":"Clinical Trial of the Safety and Immunogenicity of a Tetravalent Dengue Virus Vaccine Admixture TV005 in the Elderly Aged 50-70 Years in Taiwan","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2018-10-15","conditions":"Dengue","enrollment":252},{"nctId":"NCT03930017","phase":"","title":"Pregnancy, Arsenic and Immune Response","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2018-10-14","conditions":"Arsenic--Toxicology, Immunologic Disorders Complicating Pregnancy, Vaccine Response Impaired","enrollment":784},{"nctId":"NCT03658629","phase":"PHASE2","title":"Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults","status":"TERMINATED","sponsor":"Novavax","startDate":"2018-09-24","conditions":"Influenza, Human","enrollment":1375},{"nctId":"NCT04959344","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a Klebsiella Pneumoniae Tetravalent Bioconjugate Vaccine (Kleb4V)","status":"COMPLETED","sponsor":"LimmaTech Biologics AG","startDate":"2021-07-05","conditions":"Klebsiella Pneumoniae Infection","enrollment":166},{"nctId":"NCT03525119","phase":"PHASE3","title":"Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-05-16","conditions":"Healthy Volunteers","enrollment":900},{"nctId":"NCT05494047","phase":"PHASE3","title":"Phase Ⅲ, Clinical Trial to Compare an Inactivated Quadrivalent Influenza Vaccine and a Licensed Vaccine in Chile","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2022-07-14","conditions":"Influenza, Vaccines","enrollment":1600},{"nctId":"NCT03947775","phase":"PHASE2","title":"HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-09-01","conditions":"Anal Intraepithelial Neoplasia, Anal Cancer, Human Papilloma Virus","enrollment":228},{"nctId":"NCT05383625","phase":"PHASE3","title":"Gardasil Versus Cervarix in the Treatment of Warts","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2020-09-01","conditions":"Verruca Viral","enrollment":50},{"nctId":"NCT02827162","phase":"","title":"Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-03-29","conditions":"Dengue Fever, Dengue Haemorrhagic Fever","enrollment":334},{"nctId":"NCT00875524","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-03","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":180},{"nctId":"NCT01550289","phase":"PHASE2","title":"Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-03","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":189},{"nctId":"NCT00788151","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-09-26","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":300},{"nctId":"NCT01983553","phase":"","title":"Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-09-10","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":3203},{"nctId":"NCT03308825","phase":"PHASE4","title":"Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-09-11","conditions":"Influenza, Flu","enrollment":240},{"nctId":"NCT03617523","phase":"PHASE4","title":"Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-10","conditions":"Influenza","enrollment":240},{"nctId":"NCT02915302","phase":"PHASE4","title":"Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-09-23","conditions":"Influenza","enrollment":1950},{"nctId":"NCT02908269","phase":"PHASE4","title":"Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-09-15","conditions":"Influenza","enrollment":180},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT01436396","phase":"PHASE3","title":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09-07","conditions":"Dengue, Dengue Hemorrhagic Fever, Yellow Fever","enrollment":792},{"nctId":"NCT02992418","phase":"PHASE3","title":"Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-12-19","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":688},{"nctId":"NCT02993757","phase":"PHASE3","title":"Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-12-01","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease","enrollment":528},{"nctId":"NCT01411241","phase":"PHASE3","title":"Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-07-18","conditions":"Dengue, Dengue Hemorrhagic Fever","enrollment":720},{"nctId":"NCT02979535","phase":"PHASE3","title":"Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-16","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease","enrollment":480},{"nctId":"NCT01254422","phase":"PHASE3","title":"Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-12-02","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":250},{"nctId":"NCT01943825","phase":"PHASE2","title":"Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-11-05","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":90},{"nctId":"NCT02824198","phase":"PHASE2","title":"Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-01","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":118},{"nctId":"NCT02628444","phase":"PHASE2","title":"Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-05-02","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":1050},{"nctId":"NCT01488890","phase":"PHASE2","title":"Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-12-06","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":390},{"nctId":"NCT02623725","phase":"PHASE2","title":"Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-04-14","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":251},{"nctId":"NCT01374516","phase":"PHASE3","title":"Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-06-08","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Dengue","enrollment":20869},{"nctId":"NCT00880893","phase":"PHASE2","title":"Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-04-07","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Dengue Virus","enrollment":1198}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":277,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Gardasil"],"phase":"marketed","status":"active","brandName":"Tetravalent Vaccine","genericName":"Tetravalent Vaccine","companyName":"Instituto Nacional de Salud Publica, Mexico","companyId":"instituto-nacional-de-salud-publica-mexico","modality":"Biologic","firstApprovalDate":"","aiSummary":"A tetravalent vaccine stimulates the immune system to produce antibodies and cellular immunity against four distinct pathogenic targets or strains. Used for Protection against four dengue serotypes (dengue tetravalent vaccine).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}